The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Goodlife
if he`s an ex director, then he has nothing to do with the company anymore, He does not have to disclose anything to anyone including the company about any of his holdings.
unfortunately who ever is selling, is all but guess work to us.
we just have to wait until he or she has finished.
Kong
Not sure if this has been posted before but if it has then I apologise.
Lord James Wallasley will become CEO of Angra once we recieve the FCA licence.
His CV is excellent with immense knowledge of Asia which seems where this company wants to target.
Having just looked on companies house he became a Director of Angra on 31st August 2023
So this has been in the planning since then.
The ducks are all lined up !!!
Just need the licence to drop
It seems the seller is still in our midst.
I presume the Duke is keeping the SP up with his purchasers.
For the long term holders and the people that still want to invest more, you need to be thankfull we are still down here so you can purchase more.
once the seller has gone, I think we will move up to the next holding point, before news of any licences, Once they have arrived, thats when the fireworks should arrive.
2024 should be a very good year for the GST holders and some , providing they can hold their nerve, should become very wealthy.
GLA
Kong
Yes I totally agree Lloyd
They are 3 months into the second half of the financial year , so with both statements. They already can see a marked increase in revenues from the previous 6 months .
Do we wait u til end of July for news of revenue or do we get an insight earlier.
The company would benefit of a higher share price if they needed anymore funding .
Interesting times coming in the first half of 2024
Revenues were limited whilst the GS Money offerings were rolled out and the Board anticipates revenues to grow in the second half of the financial year.
The above taken from the chairman’s statement.
Note the company anticipates revenue to grow in the second half of the year.
We are already 3 months into the second half !
I suspect they can see revenues are already growing and with what they can see and what they know, the next 3 months will be good revenue making.
Things seems to be coming together nicely
I’m struggling to understand the value in this company right now and the potential it has
Brokers valuing this at circa 50p a share and it’s only 8p !!!
Nuts
McGurk
I note how anti Avacta you are and in particular to Alisitar Smith.
If you listen to the VOX interview from 2 days ago, around 9.30 onwards.
AS clearly states that they are wanting the phase 2 fortnightly study to commence early 2024 in the USA, with a view of completing 2 cohorts by june.
He also states that, if this has a successful outcome, it will be a game changer and a straight road to market aproval
I hope that registers a little bit more mcGurk
That’s a fair chunk dibs
I also note Oxford have employed a new person for the work on nanodes
Good news for tintra holders
Timster
if Data is not going to be very good then yes a wednesday 7am rns would fit.
But, up to and including cohort 6. AS has been very bullish including announcing a PARADIGM shift in future chemo.
Cohort 7 finished around nov 8th. AS mentioned AVACTA would release data before end Q4 to include all cohorts up to cohort 6 but may also include some of cohort 7.
I doubt vey much cohort 7 was that bad to give all the other data a dissapointing result, it cant. the previous data is written in stone, and cohort 7 cant change that.
So for me the data should be good.
Therefore we should see data release before next monday to give shareholders a chance to analyse and to create questions for the board.
I would also expect results from cohort 7 to be announced before the morning of the meeting.
other news regarding fortnightly doses and partnering should come after the meeting, whether its before the end of the year or early next year is anyones guess